- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
Patent holdings for IPC class A61K 31/53
Total number of patents in this class: 4061
10-year publication summary
|
236
|
203
|
227
|
273
|
288
|
311
|
306
|
323
|
333
|
250
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4757 |
103 |
| Shionogi & Co., Ltd. | 885 |
80 |
| Gilead Sciences, Inc. | 2243 |
55 |
| Janssen Pharmaceutica N.V. | 3150 |
54 |
| Novartis AG | 10174 |
45 |
| Servier Pharmaceuticals, LLC | 136 |
45 |
| Incyte Corporation | 1070 |
40 |
| The Regents of the University of California | 20868 |
38 |
| Hoffmann-La Roche Inc. | 3832 |
37 |
| F. Hoffmann-La Roche AG | 7796 |
35 |
| Takeda Pharmaceutical Company Limited | 2698 |
34 |
| Blueprint Medicines Corporation | 259 |
32 |
| Madrigal Pharmaceuticals, Inc. | 86 |
30 |
| Taisho Pharmaceutical Co., Ltd. | 847 |
30 |
| AstraZeneca AB | 2817 |
25 |
| Skyhawk Therapeutics, Inc. | 151 |
25 |
| Genentech, Inc. | 4123 |
24 |
| Bayer Pharma AG | 1009 |
23 |
| Incyte Holdings Corporation | 626 |
23 |
| Eisai R&D Management Co., Ltd. | 1163 |
23 |
| Other owners | 3260 |